MedPath

Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery

Phase 4
Active, not recruiting
Conditions
Rectal Adenocarcinoma
Rectum Neoplasm
Colorectal Neoplasms
Rectum Carcinoma
Colorectal Cancer
Colorectal Carcinoma
Surgical Site Infection
Surgery--Complications
Interventions
Drug: Oral Antibiotics
Drug: Placebo
Drug: Mechanical Bowel Preparation
Registration Number
NCT04281667
Lead Sponsor
Helsinki University Central Hospital
Brief Summary

MOBILE2 is a randomized controlled trial comparing mechanical and oral antibiotic bowel preparation to mechanical bowel preparation only in patients undergoing anterior rectal resection with primary anastomosis. Primary endpoint is Comprehensive Complication Index within 30 days from surgery.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
604
Inclusion Criteria
  • Patients scheduled for anterior rectal resection with primary anastomosis
Exclusion Criteria
  • Emergency operation
  • Bowel obstruction
  • Existing stoma
  • Other reason preventing mechanical bowel preparation
  • Allergy to neomycin or metronidazole
  • Age < 18 years
  • Lack of co-operation

Exclusion criteria after randomization:

  • Patient did not undergo surgery
  • Anterior resection was not performed
  • Colonic anastomosis was not performed

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Mechanical Bowel Preparation and Oral AntibioticsOral AntibioticsMechanical Bowel Preparation and Oral Antibiotics
Mechanical Bowel Preparation and Oral AntibioticsMechanical Bowel PreparationMechanical Bowel Preparation and Oral Antibiotics
Mechanical Bowel Preparation OnlyPlaceboMechanical Bowel Preparation Only
Mechanical Bowel Preparation OnlyMechanical Bowel PreparationMechanical Bowel Preparation Only
Primary Outcome Measures
NameTimeMethod
Comprehensive Complication IndexWithin 30 days from surgery

Comprehensive Complication Index score

Secondary Outcome Measures
NameTimeMethod
Surgical Site InfectionWithin 30 days from surgery

Surgical site infection as defined by CDC

Lenght of hospital stayWithin hospital stay, estimated on average 7 days

Lenght of hospital stay

MortalityWithin 90 days from surgery

Mortality

Adjuvant therapyWithin 6 months from surgery

Patients receiving adjuvant therapy divided by patients needing adjuvant therapy

Anastomotic dehiscenceWithin 30 days from surgery

Anastomotic dehiscence

Trial Locations

Locations (3)

Turku University Hospital

🇫🇮

Turku, Finland

Helsinki University Hospital

🇫🇮

Helsinki, Finland

Tampere University Hospital

🇫🇮

Tampere, Finland

© Copyright 2025. All Rights Reserved by MedPath